Biotech companies at TPD Summit 2026
Oct 26–29, 2026 Boston, MA ~300 attendees Website
46 biotech companies are at TPD Summit 2026 — 61 presentations on the program. Most represented: Nurix Therapeutics (4 on the program), Protai (2 on the program), Arvinas (2 on the program). 13 of them have their own page in this guide. As of Oct 20, 2026.
Topic
Top represented
Showing 1–14 of 46 organizations
| Organization | TPD Summit 2026 Attendance |
|---|---|
Nurix Therapeutics San Francisco, CA | ◇Industry Partner |
Clinical-stage biotech developing targeted protein degraders, including BTK degraders, for cancer and inflammatory diseases. | Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy Talk Tue Oct 27 12:30pm Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy Talk Thu Oct 29 9:00am Session Details to be Announced AI & computational design |
Combines proteomics and AI to discover drug targets, biomarkers and degraders. | Panel Tue Oct 27 3:10pm Talk Wed Oct 28 11:30am Proteomics & AI Platform Maps Degrader-Induced Ternary Complex Diversity to Enable Rational Degrader Design AI & computational designScreening, assays & proteomics Panel Thu Oct 29 10:00am |
Arvinas New Haven, CT | |
Biotech developing PROTAC protein degraders for cancer and neurological diseases. | Talk Tue Oct 27 8:30am Degradation Delivered – What the First TPD Approval Means for the Future of the Field Translational & clinical developmentInvestment, partnering & strategy |
Foghorn Therapeutics Cambridge, MA | |
Clinical-stage biotech targeting the chromatin regulatory system with small molecules and protein degraders for cancer. | Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy Talk Thu Oct 29 10:30am Proximity by Design: Harnessing Induced Proximity for Challenging Targets Degrader discovery & design |
C4 Therapeutics Watertown, MA | |
Clinical-stage biotech developing small-molecule targeted protein degraders for cancer. | Chair Tue Oct 27 8:20am Chair’s Opening Remarks Investment, partnering & strategy Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy Talk Thu Oct 29 11:45am |
Develops cancer therapeutics built on p27 biology, including molecular glue stabilizers, for drug-resistant cancers. | Panel Tue Oct 27 3:10pm Talk Thu Oct 29 12:15pm Locktacs for Intrinsically Disordered Proteins: First-in-Class p27 Molecular Glue Stabilizers Induced proximity beyond degradation |
Monte Rosa Therapeutics Boston, MA | |
Clinical-stage biotech developing molecular glue degraders from a proteomics-driven discovery platform, for cancer and immune diseases. | Chair Thu Oct 29 8:50am Chair’s Opening Remarks AI & computational design Talk Thu Oct 29 1:45pm Scaling Proteomics for High-Throughput CRBN Target Discovery Screening, assays & proteomics Chair Thu Oct 29 2:45pm Chair’s Closing Remarks Screening, assays & proteomics |
Indiana biotech discovering small-molecule degraders of proteins that cause neurodegenerative disease, starting from an APP degrader. | Talk Wed Oct 28 4:15pm Molecular Glue Degrader–Induced Co-Degradation of Mutant KRAS & CRAF Drives In Vivo Responses Degrader discovery & design Talk Thu Oct 29 2:15pm |
Develops targeted protein degraders that disrupt cancer cell fitness, including the PIP4K2C degrader LRK-4189. | Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy |
Biotech developing targeted protein degraders. | Chair Thu Oct 29 8:20am Chair’s Opening Remarks Degrader conjugates & tissue targeting Chair Thu Oct 29 2:45pm Chair’s Closing Remarks Degrader discovery & design |
Develops targeted protein degraders that use a new E3 ligase, aiming to reduce hematologic toxicity. | Talk Tue Oct 27 12:30pm |
Develops targeted protein stabilization therapeutics that recruit deubiquitinases to rescue proteins rather than degrade them. | Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy Talk Wed Oct 28 2:00pm The Journey to DUBTAC Clinical Candidates Induced proximity beyond degradation |
NEOsphere Biotechnologies Martinsried, Germany | ◇Program Partner |
Drug discovery company using high-throughput proteomics to find molecular glue degraders and profile their selectivity, partnering programs with drug developers. | Talk Tue Oct 27 12:00pm A Proteome-Wide Screening Engine Delivering Partner-Ready Molecular Glue Degraders at Scale Screening, assays & proteomics |
Biotech developing cancer therapies that target cell state, including an oral KAT2A/B degrader for blood cancers. |
Instantly find 20 buyers from biotech companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse TPD Summit 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by the TPD & Induced Proximity Summit or its organizers. Submit a correction